This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope
by Zacks Equity Research
With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.
Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra's (IART) Q3 Earnings Top, Gross Margin Declines
by Zacks Equity Research
Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.
Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 19.44% and 1.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.
Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Penumbra (PEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut
by Zacks Equity Research
Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.
Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 2.50% and 0.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Artivion (AORT) Soars 10.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.
Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integra (IART) Gains From Innovation Amid Cost Constraints
by Zacks Equity Research
Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.
Integra (IART) Q1 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.
IART vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. EW: Which Stock Is the Better Value Option?
Integra LifeSciences (IART) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 8.82% and 3.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stock Earnings Roster for Apr 27: BSX, HOLX & More
by Riya Anand
Medical device stocks' Q1 earnings will likely reflect rebound in base business. Let's see how Boston Scientific (BSX), Hologic (HOLX), Align Technology (ALGN) and Integra (IART) will fare in Q1.
Here's Why You Should Retain Integra (IART) Stock For Now
by Zacks Equity Research
Investors are optimistic about Integra (IART), given the strength in its CSS arm and notable product launches.
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) Down 3.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair
by Zacks Equity Research
Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.
Is Integra LifeSciences (IART) a Worthy Value Investor Pick?
by Zacks Equity Research
Let's see if Integra LifeSciences (IART) stock is a good choice for value-oriented investors right now from multiple angles.